Sartorius AG

SRT

Equity

ISIN DE0007165607 / Valor 346909

Xetra (2024-12-23)

EUR 176.00-0.23%

Sartorius AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sartorius AG is a leading company in the biopharmaceutical industry, offering a wide range of products and services in the production of biopharmaceuticals. The Bioprocess Solutions Division provides essential technologies for filtration, fermentation, cell cultivation, and fluid management. Additionally, the Lab Products & Services Division offers innovative solutions for bioanalytics, laboratory products, consumables, and services to pharmaceutical, biopharmaceutical, and academic research laboratories. Sartorius is recognized as a market leader in laboratory balances, pipettes, and lab consumables, catering to the needs of various scientific and research institutions.

Summarized from source with an LLMView SourceSector: Industrials

Sales Revenue and Order Intake

In the first nine months of 2024, Sartorius AG reported a slight decline in sales revenue by 2.0 percent in constant currencies, amounting to 2,474 million euros. However, the company experienced a significant increase in order intake, which rose by 6.6 percent in constant currencies to 2,326 million euros. This positive trend in order intake indicates a growing demand for Sartorius AG's products and services.

Profitability and EBITDA Margin

Sartorius AG maintained a robust underlying EBITDA margin of 27.7 percent for the first nine months of 2024, despite a decrease in underlying EBITDA by 6.4 percent to 686 million euros. The company attributes this stability to the positive effects of its efficiency program, which is expected to contribute further in the fourth quarter of the year.

Bioprocess Solutions Division Performance

The Bioprocess Solutions Division of Sartorius AG recorded sales revenue nearly at the previous year's level, with a slight decline of 0.8 percent in constant currencies, totaling 1,962 million euros. The division saw a significant increase in order intake by 8.4 percent in constant currencies, driven by growing demand in the consumables business, despite industry-wide investment hesitancy.

Lab Products & Services Division Challenges

The Lab Products & Services Division faced challenges due to weak end markets, particularly in China, resulting in a sales revenue decline of 6.5 percent in constant currencies to 511 million euros. Despite this, order intake stabilized at the previous year's level, showing a slight increase of 0.3 percent in constant currencies.

Outlook for Full-Year 2024

Sartorius AG has confirmed its guidance for the full year 2024, expecting sales revenue to be on par with the previous year, with a low single-digit range of negative to positive development. The company anticipates an underlying EBITDA margin between 27 to 29 percent, supported by its ongoing efficiency program, which is projected to contribute over 100 million euros positively.

Summarized from source with an LLMView Source

Key figures

-33.0%1Y

-63.8%3Y

%5Y

Performance

47.6%1Y

45.8%3Y

45.9%5Y

Volatility